Skip to main content

Lifecore Biomedical, Inc.

corporate_fare Company Profile

Lifecore Biomedical, Inc.

LFCR·NASDAQ·Life Sciences·CIK 0001005286

Lifecore Biomedical, Inc. is a contract development and manufacturing organization (CDMO) based in Chaska, Minnesota. The company specializes in the development, cGMP manufacturing, and aseptic filling of complex and highly viscous sterile injectable pharmaceutical drug and medical device products in syringes, vials, and cartridges. Lifecore is a leading U.S. manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA), utilizing a proprietary, fermentation-based HA process developed in 1981. They manufacture HA in bulk form and for use in formulated and filled syringes and vials for customer injectable products, which are used in ophthalmic and orthopedic applications, among others. Lifecore also develops highly viscous non-HA-based sterile injectable products with customers for various applications. The company's product development services include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies. Lifecore operates semi-automated Restricted Access Barrier Systems (RABS) and fully automated aseptic filling lines with isolators, supporting aseptic processing of both synthetic and biologic drug products. Manufacturing occurs across three cGMP facilities, where FDA-approved commercial drug and device products are produced. Lifecore holds certifications from regulatory agencies in Europe, Japan, Brazil, and the International Organization for Standardization (ISO). The company's HA capabilities were developed in the early 1980s, and its corporate name changed from Landec Corporation to Lifecore Biomedical, Inc. in 2022 to reflect its focus on the CDMO business.

Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for LFCR at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Lifecore Biomedical Lands Key Commercial Manufacturing Pact for Aesthetic Product
  • Lifecore Biomedical Reports Improved Cash Flow & Legal Resolutions Amidst Adverse Internal Control Opinion & Reduced 2026 Revenue Forecast
  • Lifecore Biomedical Reports Strong Q4, But Issues Significantly Lower 2026 Guidance and Discloses Major Preferred Stock Redemption Risk
  • Customer Loss Expected for Lifecore Biomedical, Signaling Revenue Headwind

Financial Snapshot

Fiscal year ended May 25, 2025
Revenue
$128.87M
Net Income
-$38.72M
Diluted EPS
-$1.27
Op. Cash Flow
-$206K
Free Cash Flow
-$13.62M
Gross Profit
$40.3M
Operating Income
-$17.25M
Cash & Equivalents
$8.27M
Total Debt
$133.87M
Debt / Equity
100.20×
Net Margin
-30.0%
Shares Outstanding
37.03M sh
Source: 10-K · filed 2025-08-07 · accession 0001005286-25-000108
$6.37
52-week range · as of 2026-11-04 $3.63 – $8.98
Market cap
$242.22M
Volume
218.7K (0.6× avg)
3-mo avg 383K
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LFCR - Filings & News (Page 2)

LFCR
Mar 23, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.07
Real-time Price: $6.37 info
Change: +$2.30 (+57%) info
Market Cap: $242.218M info
LFCR
Mar 16, 2026, 8:15 AM EDT
Filing Type: 10-KT
Importance Score:
8
Price at Filing: $6.82
Real-time Price: $6.37 info
Change: -$0.450 (-7%) info
Market Cap: $242.218M info
LFCR
Mar 16, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.82
Real-time Price: $6.37 info
Change: -$0.450 (-7%) info
Market Cap: $242.218M info
LFCR
Mar 16, 2026, 8:03 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $6.82
Real-time Price: $6.37 info
Change: -$0.450 (-7%) info
Market Cap: $242.218M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets